Enanta Pharmaceuticals (ENTA) Cash & Equivalents (2012 - 2026)

Enanta Pharmaceuticals has reported Cash & Equivalents for 15 years, with the latest figure at $34.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 41.99% year-over-year to $34.9 million; the trailing twelve-month figure through Mar 2026 stood at $34.9 million (down 41.99% YoY), and the FY2025 full-year result was $32.3 million, down 13.25% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $34.9 million, down from $37.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $95.2 million in Q2 2023, with the low at $28.4 million in Q2 2022.
• Historically, Cash & Equivalents has averaged $51.8 million across 5 years, with a median of $42.2 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 516.54% — and 2024, when it plunged 62.41%.
• Enanta Pharmaceuticals' Cash & Equivalents stood at $42.2 million in 2022, then retreated by 5.42% to $39.9 million in 2023, then soared by 111.23% to $84.3 million in 2024, then sank by 55.62% to $37.4 million in 2025, then retreated by 6.7% to $34.9 million in 2026.
• The last three Cash & Equivalents figures came in at $34.9 million (Q1 2026), $37.4 million (Q4 2025), and $32.3 million (Q3 2025), per Business Quant data.